Antibody Drug Conjugates Market — Global Industry Insights,
Trends, Outlook, and Opportunity Analysis, 2018-2026
Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad
therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to
mark and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise
antibodies linked to a biologically active cytotoxic drug.
By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle
judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill
only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional
phenomenon of killing only cancer cells increase the importance of use of ADCs, which would
indirectly boost growth of the global antibody drug conjugates market.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/181
Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to
over US$ 10 billion over the forecast period of market
In terms of marketing, three antibody drug conjugates have received regulatory approval. The U.S.
FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute
myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two
antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab
vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and
Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates
molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the
45 molecules, around 25% are under Phase II or Phase III of development. Frequently used
cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine
and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug